Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia

Diagnostic Microbiology and Infectious Disease

Volumn 60, Issue 1, 2008, Pages 59-64

  Bhavnani, Sujata M ^a   Ambrose, Paul G ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Community acquired pneumonia; Fluoroquinolones; Gemifloxacin

Indexed keywords

CEFTRIAXONE; CEFUROXIME; GEMIFLOXACIN; MACROLIDE;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FOLLOW UP; HOSPITALIZATION; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CEFUROXIME; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; FEMALE; FLUOROQUINOLONES; HUMANS; MACROLIDES; MALE; MIDDLE AGED; NAPHTHYRIDINES; PNEUMONIA;

EID: 36849018498     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.07.006     Document Type: Article

References (19)

1. Bartlett J.G., Breiman R.F., Mandell L.A., and File Jr. T.M. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin. Infect. Dis. 26 (1998) 811-838
2. Dresser L.D., Niederman M.S., and Paladino J.A. Cost-effectiveness of gatifloxacin versus ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 119 (2001) 1439-1448
3. Fine M.J., Smith M.A., Carson C.A., Mutha S.S., Sankey S.S., Weissfeld L.A., and Kapoor W.N. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 275 (1996) 134-141
4. In: Fleming T. (Ed). Red Book. Pharmacy's Fundamental Reference™. 108th Ed (2004), Blackwell Publishing, Boston (MA)
5. Hatoum H.T. Microcost analysis of inpatient dispensing and administration of oral solids. Am. J. Hosp. Pharm. 47 (1990) 800-805
6. Heffelfinger J.D., Dowell S.F., and Jorgensen J.H. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch. Intern. Med. 160 (2000) 1399-1408
7. Hitt C.M., Nightingale C.H., and Quintiliani R. Cost comparison of single daily intravenous doses of ceftriaxone versus continuous infusion of cefotaxime. Am. J. Health Syst. Pharm. 54 (1997) 1614-1618
8. Kuti J.L., Le T.N., Nightingale C.H., Nicolau D.P., and Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from I.V. to oral. Am. J. Health Syst. Pharm. 59 (2002) 2209-2215
9. Lode H., File T.M., Mandell L., Ball P., Pypstra R., and Thomas M. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multi-center study of clinical efficacy and tolerability. Clin. Ther. 24 (2002) 1915-1936
10. Mandell L.A., and Marrie T.J. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin. Infect. Dis. 31 (2000) 383-421
11. Mandell L.A., and Wunderink R.G. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44 (2007) S27-S72
12. McKinnon P.S., Paladino J.A., Grayson M.L., Gibbons G.W., and Karchmer A.W. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin. Infect. Dis. 24 (1997) 57-63
13. Niederman M.S., McCombs J.S., Unger A.N., Kumar A., and Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther. 20 (1998) 820-837
14. Paladino J.A., Gudgel D.L., Forrest A., and Niederman M.S. Cost-effectiveness of IV-to-oral switch therapy. Chest 122 (2002) 1271-1279
15. Paladino J.A., and Fell R.E. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann. Pharmacother. 28 (1994) 384-389
16. RBRVS EZ-Fees®, (2004) Yale Wasserman, DMD Medical Publishers, Ltd.
17. Richerson M.A., Ambrose P.G., Quintiliani R., and Nightingale C.H. Cost-effectiveness analysis of alternative antibiotic therapies for hospitalized patients with community-acquired pneumonia. Infect. Dis. Clin. Pract. 7 (1998) 227-233
18. Tice A.D., Turpin R.S., Hoey C.T., Lipsky B.A., Wu J., and Abramson M.A. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections. Am. J. Health Syst. Pharm. 64 (2007) 1080-1086
19. Wasserfallen J.B., Erard V., Cometta A., Calandra T., and Lamy O. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. Eur. Resp. J. 24 (2004) 644-648